This study is a post-marketing surveillance to monitor safety and efficacy of remifentanil
during various surgeries and identify SAEs, adverse drug reactions, and unexpected AEs not
described as precautions or warnings and to identify prognostic factors that have an effect
on the AEs and to assess effectiveness of remifentanil in real clinical practices after
marketing.
The subjects are patients prescribed for remifentanil by the investigators at the sites based
on prescription information in normal clinical practices.